Afyon Kocatepe University, Faculty of Medicine, Department of Medical Biochemistry, Afyonkarahisar, Turkey.
J Psychopharmacol. 2017 Nov;31(11):1453-1459. doi: 10.1177/0269881117715608. Epub 2017 Sep 6.
An increased risk for metabolic syndrome (MS) has been described for people with psychotic and mood disorders. The aim of this study was to determine the influence of valproic acid (VPA) treatment on adiponectin, leptin levels and oxidative stress in bipolar disorder (BD).
Forty patients with BD receiving VPA monotherapy and 20 healthy control subjects were included in this study. BD patients were divided into two groups with and without MS as group 1 and group 2, respectively. Twenty BD patients diagnosed according to the Diagnostic and Statistical Manual for Mental Disorders (DSM IV) were assessed for MS according to the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III) criteria. Adiponectin, leptin, protein carbonyls, sulfhydryl (-SH) and malondialdehyde (MDA) levels were measured in 40 BD patients and 20 control subjects.
Serum adiponectin levels were significantly lower in group 1 patients than in group 2 and control subjects ( p<.001). Serum leptin levels were significantly higher in group 1 patients than in group 2 and control subjects ( p<.001). Serum -SH levels were significantly lower in group 2 patients than in group 1 ( p<.001) and control subjects ( p<.05). Serum carbonyl levels were significantly higher in group 1 and group 2 patients than in control subjects ( p<.001). Serum MDA levels were significantly higher in group 1 patients than in group 2 and control subjects ( p<.001).
These results provide further evidence that VPA treatment for patients with BD contributed to the metabolic disturbances, such as the decreased serum adiponectin and -SH levels, as well as the increased serum leptin, MDA and carbonyl levels.
患有精神病和情绪障碍的人患代谢综合征（MS）的风险增加。本研究的目的是确定丙戊酸（VPA）治疗对双相情感障碍（BD）患者脂联素、瘦素水平和氧化应激的影响。
本研究纳入了 40 名接受 VPA 单药治疗的 BD 患者和 20 名健康对照者。BD 患者分为两组，有代谢综合征（MS）的为组 1，无代谢综合征的为组 2。根据精神障碍诊断与统计手册（DSM-IV）诊断的 20 名 BD 患者根据国家胆固醇教育计划（NCEP）成人治疗小组（ATP III）标准评估 MS。测量了 40 名 BD 患者和 20 名对照者的脂联素、瘦素、蛋白羰基、巯基（-SH）和丙二醛（MDA）水平。
组 1 患者血清脂联素水平明显低于组 2和对照组（p<.001）。组 1 患者血清瘦素水平明显高于组 2和对照组（p<.001）。组 2 患者血清 -SH 水平明显低于组 1（p<.001）和对照组（p<.05）。组 1 和组 2 患者血清羰基水平明显高于对照组（p<.001）。组 1 患者血清 MDA 水平明显高于组 2 和对照组（p<.001）。
这些结果进一步表明，BD 患者 VPA 治疗导致代谢紊乱，如血清脂联素和 -SH 水平降低，以及血清瘦素、MDA 和羰基水平升高。
